title: Ligands of the peripheral benzodiazepine receptor are potent inhibitors of Plasmodium falciparum and Toxoplasma gondii in vitro.
abstract: The increase in resistance of the malaria parasite Plasmodium falciparum to currently available drugs demands the development of new antimalarial agents. In this quest, we have found that ligands to the peripheral benzodiazepine receptor such as flurazepam, an agonist of the benzodiazepine family, and PK11195, an antagonist derived from isoquinoline, were active against Plasmodium falciparum. These two compounds effectively and rapidly inhibited parasite growth in vitro, irrespective of parasite resistance to chloroquine and mefloquine. Treatment with both drugs induced a sharp and consistent decline in parasitemia, a complete inhibition of parasite replication, and the destruction of parasites within the host red blood cells. Using electron microscopy, we showed that dramatic morphological changes, involving swollen endoplasmic reticulum and the reduction of hemozoin, were consistent with parasite death. The potent activities of flurazepam and PK11195 were also evaluated for antagonist or synergistic effects with currently used antimalarial drugs such as chloroquine and mefloquine. Moreover, flurazepam was found to be active against Toxoplasma gondii, another member of the phylum Apicomplexa. Taken together, our results indicated that benzodiazepines could be considered promising candidates in the treatment of both malaria and toxoplasmosis.
authors.affiliation: Equipe de Parasitologie Moléculaire, Laboratoire de Chimie Biologique, CNRS UMR 8576, Paris, France.
authors.forename: Florence
authors.initials: F
authors.lastname: Dzierszinski
authors.forename: Alexandra
authors.initials: A
authors.lastname: Coppin
authors.forename: Marlene
authors.initials: M
authors.lastname: Mortuaire
authors.forename: Etienne
authors.initials: E
authors.lastname: Dewailly
authors.forename: Christian
authors.initials: C
authors.lastname: Slomianny
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Ameisen
authors.forename: Frederic
authors.initials: F
authors.lastname: DeBels
authors.forename: Stanislas
authors.initials: S
authors.lastname: Tomavo
mesh_terms: D000818:Animals; D000962:Antimalarials / Q000494:pharmacology; D002738:Chloroquine / Q000494:pharmacology; D004912:Erythrocytes / Q000469:parasitology; D005347:Fibroblasts / Q000469:parasitology; D005479:Flurazepam / Q000494:pharmacology*; D058785:GABA-A Receptor Agonists; D058787:GABA-A Receptor Antagonists; D006420:Hemeproteins / Q000378:metabolism; D006801:Humans; D007546:Isoquinolines / Q000494:pharmacology*; D008024:Ligands; D015767:Mefloquine / Q000494:pharmacology; D021261:Parasitic Sensitivity Tests; D010963:Plasmodium falciparum / Q000187:drug effects* / Q000254:growth & development; D014122:Toxoplasma / Q000187:drug effects* / Q000254:growth & development
chemical_list: D000962:Antimalarials; D058785:GABA-A Receptor Agonists; D058787:GABA-A Receptor Antagonists; D006420:Hemeproteins; D007546:Isoquinolines; D008024:Ligands; C020753:hemozoin; D002738:Chloroquine; D005479:Flurazepam; D015767:Mefloquine; C037850:PK 11195